Please use this identifier to cite or link to this item:
Title: Human fibroblast interferon in tears of patients with picornavirus epidemic conjunctivitis
Authors: Langford, M.P.
Yin-Murphy, M. 
Ho, Y.M.
Barber, J.C.
Baron, S.
Stanton, G.J.
Issue Date: 1980
Citation: Langford, M.P., Yin-Murphy, M., Ho, Y.M., Barber, J.C., Baron, S., Stanton, G.J. (1980). Human fibroblast interferon in tears of patients with picornavirus epidemic conjunctivitis. Infection and Immunity 29 (3) : 995-998. ScholarBank@NUS Repository.
Abstract: We report the levels of coxsackievirus type A24 (CA24) and the levels and type of interferon produced early during naturally acquired picornavirus epidemic conjunctivitis. Virus levels ranging from 101.8 to 105.8 50% tissue culture infective doses per ml were detected in 29 of 37 acute (collected 1 to 4 days after onset of conjunctivitis) tear samples. Interferon (101.5 to 103.3 U/ml) was detected in 12 of 29 tear samples collected on day 1, in 2 of 6 tear samples collected on day 2, and in 1 tear sample collected on day 3 after onset of conjunctivitis. The interferon activity in pooled tear samples was completely neutralized by antiserum against human fibroblast interferon, stable at pH 2.0, and active against different viruses. In addition, the interferon activity in tears, like human fibroblast and leukocyte interferons produced in vitro, protected human and rabbit, but not mouse, cells. This is the first report of production and identification of the antigenic type of interferon induced by an enterovirus during natural infection. The early appearance of fibroblast interferon suggests that it may be an important host defense at the local site of implantation against this and possibly other enterovirus infections.
Source Title: Infection and Immunity
ISSN: 00199567
Appears in Collections:Staff Publications

Show full item record
Files in This Item:
There are no files associated with this item.

Page view(s)

checked on May 21, 2019

Google ScholarTM


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.